For US Healthcare Professionals
I am a:
Clear
At Week 24, 53% of patients in VOYAGE 1 and 48% of patients in VOYAGE 2 achieved IGA 0. At Week 48, 47% of patients in VOYAGE 1 achieved IGA 0.1,2
Consistent & Durable
In VOYAGE 1, PASI 90 response rates were consistent between doses from Weeks 20-48. In open-label extensions, PASI 90 response rates were maintained from Weeks 52-252 in VOYAGE 1 and durable joint improvement was seen at Week 100 in DISCOVER 2 based on ACR50 response rates.2-4*
Demonstrated Retention
In open-label extensions, patient retention rates were 77% for VOYAGE 1 and 76% for VOYAGE 2 through 5 years.3
No conclusions regarding efficacy or safety can be drawn from retention data.
Access & Support
Access options for all appropriate patients, regardless of insurance coverage.
TREMFYA withMe offers a simplified fulfillment experience to help patients get started quickly.
TREMFYA® is dedicated to helping overlooked and undertreated patients
As treatments continue to evolve, Johnson & Johnson is committed to studying TREMFYA® in:
Hypothetical patients.
BSA=body surface area; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; PsO=psoriasis.
*Patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may increase the response rate in an as-observed analysis. The same patients may not have responded at each time point.
†BSA criteria of 2%-15%.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. Data on file. Janssen Biotech, Inc. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485.
IN ADULTS WITH MODERATE TO SEVERE PLAQUE PsO
